1Abranham R T, Wiederrecht G J. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996,14: 483--510.
2Ruygrok P N, Muller D W, Serruys P W. Rapamycinin cardiovascular medicine. Intern Med J, 2003, 33 : 103-109.
3McMahonLP, ChoiK M, LinT A, et al. The rapamycin-binding domain governs substrate selectivity by mammalian targer of rapamycin. Mol Cell Biol, 2002,22:7428--7438.
4Fingar D C, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP/eIF4E. Genes Dev, 2002, 16: 1472--1487.
5Stawowy P, Blaschke F, Kilimnik A, et al. Proprotein convertase PC5 regulation by PDGF-BB involves PI3-Kinase/p70s6-Kinase activation in vascular smooth muscle cells. Hypertension, 2002,39 : 399--404.
6Hashemolhosseini S, Nagamine Y, Morley S, et al.Rapamycin inhibition of the G1 to S transition is mediated by effets on Cyclin D1 mRNA and proterin stability.J Biol Chem, 1998,273: 14424--14429.
7Klugherz B, Llanos G, Lieuallen W, et al. Stent-based delivery of sirolinus for the prevention of restenosis. J Am Coil Cardiol, 2000,35 :58-- 58.
8Lima V C, Rosa W C, Arruda J A, et al. Efficacy and safety of oral sirolimus to treat and prevent in-stent restenosis: Results of a pilot study. Am J Cardiol,2002,90(Suppl 6A) :11H--11H.
9Degertekin M, Serruys P W, Foley D P, Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation long-term (Up to 2 years) clinical,angiographic, and Intravascular ultrasound follow-up.Circulation, 2002,106: 1610--1613.
10Sousa J E, Costa M A, Sousa A G, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation, 2003, 107:381--383.
5DAVID ANTHONY TULIS. Rat Carotid Artery Balloon Injury Model[J]. NIH-PA Author Manuscript, 2007, 139: 1.
6MEENA SK, GARY KO. Combinatorial control of smooth muscle specific gene expression[J]. Arterioscier Thromb Vasc Biol, 2003, 23(3): 737-747.
7ZHOU CH, XIANG M, HE SY, et al. Crocetin inhibits cell cy- cle G 1IS transition through suppressing cyclin D1 and elevating p 27kip1 in vascular smooth muscle cells[J]. Phytother Res, 2010, 24(7): 975-981.
8BRAIN M, SICARI, RONNIE TROXELL, et al. C-myc and skp2 Coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-re- lated protein[J]. Endocrinology, 2012, 153(2): 861-872.
9贺争鸣,李冠明.动物实验方法替代概论[M].北京:学苑出版社,2003:164.
10HUNGERFORD JE. Development Biology of the vascular smooth muscle cell: building a multilayered vessel wall[J]. J Vasc Res, 1999, 36(1): 2-27.